Aducanumab for the treatment of Alzheimer's disease: a systematic review.

A Rahman; Hossen MA; Chowdhury MFI; S Bari; N Tamanna; Sultana SS; Haque SN; Masud A Al; Saif-Ur-Rahman KM

doi:10.1111/psyg.12944

Aducanumab for the treatment of Alzheimer's disease: a systematic review.

A Rahman
, Hossen MA
, Chowdhury MFI
, S Bari
, N Tamanna
, Sultana SS
, Haque SN
, Masud A Al
, Saif-Ur-Rahman KM

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

77 Citations (Scopus)

Abstract

Aducanumab is a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trials to evaluate the efficacy and safety of aducanumab treating AD. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. We conducted an extensive literature search using the electronic databases MEDLINE through PubMed, EMBASE, Cochrane, Web of Science, and Scopus for suitable studies on aducanumab. We considered human clinical trials of aducanumab, assessing its efficacy and adverse effects in treating AD, excluding any experimental animal studies. We included three randomised controlled trials. Studies reported that aducanumab reduced brain amyloid-beta plaques in a time- and dose-dependent manner (dose-response, P

Original language	Undefined/Unknown
Journal	Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society
DOIs	https://doi.org/10.1111/psyg.12944
Publication status	Published - 12 Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/psyg.12944

Cite this

@article{d011362a2a48468bbde776dd05449535,

title = "Aducanumab for the treatment of Alzheimer's disease: a systematic review.",

abstract = "Aducanumab is a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trials to evaluate the efficacy and safety of aducanumab treating AD. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. We conducted an extensive literature search using the electronic databases MEDLINE through PubMed, EMBASE, Cochrane, Web of Science, and Scopus for suitable studies on aducanumab. We considered human clinical trials of aducanumab, assessing its efficacy and adverse effects in treating AD, excluding any experimental animal studies. We included three randomised controlled trials. Studies reported that aducanumab reduced brain amyloid-beta plaques in a time- and dose-dependent manner (dose-response, P ",

author = "A Rahman and Hossen MA and Chowdhury MFI and S Bari and N Tamanna and Sultana SS and Haque SN and Al, \{Masud A\} and Saif-Ur-Rahman KM",

year = "2023",

month = feb,

day = "12",

doi = "10.1111/psyg.12944",

language = "Undefined/Unknown",

journal = "Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society",

}

TY - JOUR

T1 - Aducanumab for the treatment of Alzheimer's disease: a systematic review.

AU - Rahman, A

AU - MA, Hossen

AU - MFI, Chowdhury

AU - Bari, S

AU - Tamanna, N

AU - SS, Sultana

AU - SN, Haque

AU - Al, Masud A

AU - KM, Saif-Ur-Rahman

PY - 2023/2/12

Y1 - 2023/2/12

N2 - Aducanumab is a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trials to evaluate the efficacy and safety of aducanumab treating AD. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. We conducted an extensive literature search using the electronic databases MEDLINE through PubMed, EMBASE, Cochrane, Web of Science, and Scopus for suitable studies on aducanumab. We considered human clinical trials of aducanumab, assessing its efficacy and adverse effects in treating AD, excluding any experimental animal studies. We included three randomised controlled trials. Studies reported that aducanumab reduced brain amyloid-beta plaques in a time- and dose-dependent manner (dose-response, P

AB - Aducanumab is a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trials to evaluate the efficacy and safety of aducanumab treating AD. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines. We conducted an extensive literature search using the electronic databases MEDLINE through PubMed, EMBASE, Cochrane, Web of Science, and Scopus for suitable studies on aducanumab. We considered human clinical trials of aducanumab, assessing its efficacy and adverse effects in treating AD, excluding any experimental animal studies. We included three randomised controlled trials. Studies reported that aducanumab reduced brain amyloid-beta plaques in a time- and dose-dependent manner (dose-response, P

UR - https://doi.org/10.1111/psyg.12944

U2 - 10.1111/psyg.12944

DO - 10.1111/psyg.12944

M3 - Article

C2 - 36775284

JO - Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society

JF - Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society

ER -

Aducanumab for the treatment of Alzheimer's disease: a systematic review.

Abstract

UN SDGs

Access to Document

Other files and links

Cite this